# US 2015/0031756 A1 · Lentiviral vectors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031756 A1
- Document ID: US20150031756A1
- Status: Published application
- Kind: A1
- Application number: 14/449,898
- Filed: 2014-08-01
- Published: 2015-01-29
- Earliest claimed: 2004-07-21
- Applicants: Dana-Farber Cancer Institute
- Inventors: Wayne A. Marasco
- Web page: https://patentgrep.com/patent/US20150031756A1

## CPC

- C12N 15/86: Viral vectors
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/1147: {Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]}
- C07K 16/18: against material from animals or humans
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6857: {Antibody fragments}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2317/21: from primates, e.g. man
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16045: Special targeting system for viral vectors
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2810/6054: Retroviridae
- C12N 2810/6081: rhabdoviridae, e.g. VSV
- C12N 2830/003: tet inducible
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2830/60: from viruses
- C12N 2840/203: having an IRES
- C12N 2840/44: being a specific part of the splice mechanism, e.g. donor, acceptor
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to compositions containing polynucleotide vectors capable of expressing a nucleic acid encoding a fusion polypeptide on the surface of a viral particle and/or a eukaryotic cell.

## Claims

### Claim 1

A method of displaying a candidate polypeptide on the surface of a mammalian cell, comprising the steps of:
a) contacting a packaging cell with a viral display vector comprising a nucleic acid sequence encoding a fusion protein under conditions such that said packaging cell generates one or more viral particles comprising said nucleic acid sequence, wherein said fusion protein comprises:
i) a leader peptide;
ii) a candidate polypeptide;
iii) at least a portion of an immunoglobulin molecule;
iv) a transmembrane moiety; and
b) contacting said viral particles with a mammalian cell, under conditions sufficient to express said fusion protein in said mammalian cell, wherein said candidate polypeptide is displayed on the surface of the mammalian cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein said immunoglobulin molecule is further displayed on the surface of the mammalian cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein said immunoglobulin molecule comprises the hinge region, the CH2 region or the CH3 region of an IgG molecule or a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein said viral display vector is a lentiviral vector.

### Claim 5 (depends on 1)

The method of claim 1, wherein said candidate polypeptide is an antibody or fragment thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein said antibody is a single chain antibody, a domain antibody, a diabody, or Fab fragment.

### Claim 7 (depends on 1)

The method of claim 1, wherein said candidate polypeptide is derived from a library.

### Claim 8 (depends on 4)

The method of claim 4, wherein said lentiviral vector is obtained from a lentivirus selected from the group consisting of human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), visna virus, caprine arthritis-encephalitis virus (CAEV), bovine immune deficiency virus (BIV), bovine leukemia virus (BLV), and feline immunodeficiency virus (FIV).

### Claim 9 (depends on 1)

The method of claim 1, wherein said packaging cell further comprises;
(i) an envelope vector comprising an env gene operably linked to a promoter and a polyadenylation sequence wherein said env gene encodes a functional envelope protein and;
(ii) a helper vector comprising one or more viral structural genes.

### Claim 10 (depends on 1)

The method of claim 1, wherein said candidate polypeptide is expressed on the surface of said viral particles prior to contacting said viral particles with said mammalian cell.

### Claim 11 (depends on 1)

The method of claim 1, wherein said transmembrane moiety is a viral transmembrane moiety or a mammalian transmembrane moiety.

### Claim 12 (depends on 1)

The method of claim 1, wherein said mammalian cell is a Ramos Burkitt's lymphoma cell.

### Claim 13

A method of displaying a candidate polypeptide on the surface of a viral particle, comprising the step of contacting a packaging cell with a viral display vector comprising a nucleic acid sequence encoding a fusion protein under conditions such that said packaging cell generates one or more viral particles comprising the fusion protein, such that said candidate polypeptide is displayed on the surface of the viral particle, wherein said fusion protein comprises:
i) a leader peptide;
ii) a candidate polypeptide;
iii) at least a portion of an immunoglobulin molecule;
iv) a transmembrane moiety; and
v) an envelope incorporation signal.

### Claim 14 (depends on 13)

The method of claim 13, wherein said candidate polypeptide is an antibody or fragment thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein said antibody is a single chain antibody, a domain antibody, a diabody, or Fab fragment.

### Claim 16 (depends on 13)

The method of claim 13, wherein said candidate polypeptide is derived from a library.

### Claim 17 (depends on 13)

The method of claim 13, wherein said viral display vector is a lentiviral vector.

### Claim 18 (depends on 17)

The method of claim 17, wherein said lentiviral vector is obtained from a lentivirus selected from the group consisting of human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), visna virus, caprine arthritis-encephalitis virus (CAEV), bovine immune deficiency virus (BIV), bovine leukemia virus (BLV), and feline immunodeficiency virus (FIV).

### Claim 19 (depends on 13)

The method of claim 13, wherein said immunoglobulin molecule comprises the hinge region, the CH2 region or the CH3 region of an IgG molecule or a combination thereof.

### Claim 20 (depends on 13)

The method of claim 13, wherein said transmembrane moiety is a viral transmembrane moiety or a mammalian transmembrane moiety.

### Claim 21 (depends on 13)

The method of claim 13, wherein said packaging cell further comprises;
(i) an envelope vector comprising an env gene operably linked to a promoter and a polyadenylation sequence wherein said env gene encodes a functional envelope protein and;
(ii) a helper vector comprising one or more viral structural genes.

### Claim 22

A method of identifying a candidate polypeptide that binds to a target antigen, comprising the steps of:
a) contacting a packaging cell with a nucleic acid vector comprising a nucleic acid sequence encoding a fusion protein under conditions such said packaging cell generates one or more viral particles comprising said nucleic acid sequence, wherein said fusion protein comprises:
i) a leader peptide;
ii) a candidate polypeptide;
iii) at least a portion of an immunoglobulin molecule; and
iv) a transmembrane moiety, and
b) contacting said viral particles with one or more mammalian cells, under conditions such that said one or more mammalian cells each generate a single species of said candidate polypeptide displayed on the surface of said mammalian cells;
c) sorting said mammalian cells displaying said single species of said candidate polypeptide on the surface of said mammalian cell;
d) contacting said sorted mammalian cells with a target antigen; and
e) identifying the mammalian cells that bind to said target antigen, thereby identifying a candidate polypeptide that binds to said target antigen.

### Claim 23 (depends on 22)

The method of claim 22, further comprising repeating steps d) and e) one or more times.

### Claim 24 (depends on 22)

The method of claim 22, wherein said packaging cell further comprises;
(i) an envelope vector comprising an env gene operably linked to a promoter and a polyadenylation sequence wherein said env gene encodes a functional envelope protein and;
(ii) a helper vector comprising one or more viral structural genes.

### Claim 25 (depends on 22)

The method of claim 22, wherein said candidate polypeptide is an antibody or fragment thereof.

### Claim 26 (depends on 22)

The method of claim 22, wherein said candidate polypeptide is derived from a library.

### Claim 27 (depends on 28)

The method of claim 28, wherein said viral display vector is a lentiviral vector.

### Claim 28 (depends on 27)

The method of claim 27, wherein said lentiviral vector is obtained from a lentivirus selected from the group consisting of human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), visna virus, caprine arthritis-encephalitis virus (CAEV), bovine immune deficiency virus (BIV), bovine leukemia virus (BLV), and feline immunodeficiency virus (FIV).

### Claim 29 (depends on 22)

The method of claim 22, wherein said nucleic acid vector further comprises an nucleic acid encoding a selectable marker.

### Claim 30 (depends on 29)

The method of claim 29, wherein said selectable marker is selected from the group consisting of a green fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, a blue fluorescent protein, a ferredoxin IV protein, a luciferase protein and a aequorin protein.

### Claim 31 (depends on 22)

The method of claim 22, wherein said transmembrane moiety is a viral transmembrane moiety or mammalian transmembrane moiety.

### Claim 32

A method of affinity maturing a candidate polypeptide, comprising the steps of:
a) contacting a packaging cell with a nucleic acid vector comprising a nucleic acid sequence encoding a fusion protein, wherein said fusion protein comprises:
i) a leader peptide;
ii) a candidate polypeptide;
iii) at least a portion of an immunoglobulin molecule; and
iv) a transmembrane moiety under conditions such that the packaging cell generates one or more viral particles comprising said nucleic acid sequence;
b) contacting said one or more viral particles with one or more second mammalian cells, under conditions such that said one or more mammalian cells each generate a single species of candidate polypeptide that is displayed on the surface of said one or more mammalian cells;
c) sorting said one or more mammalian cells displaying said single species of candidate polypeptide on the surface of said mammalian cell;
d) contacting said sorted one or more mammalian cells with a target antigen;
e) identifying those mammalian cells that bind to said target antigen;
f) contacting said identified mammalian cells with a decreasing concentration of said target antigen; and
g) repeating steps e) and f) one or more times,
thereby affinity maturing a candidate polypeptide that binds to said target antigen.

### Claim 33 (depends on 32)

The method of claim 32, wherein said packaging cell further comprises;
(i) an envelope vector comprising an env gene operably linked to a promoter and a polyadenylation sequence wherein said env gene encodes a functional envelope protein and;
(ii) a helper vector comprising one or more viral structural genes.

### Claim 34 (depends on 32)

The method of claim 32, wherein said mammalian cells express activation-induced cytosine deaminase (AID) protein.

### Claim 35 (depends on 32)

The method of claim 32, wherein said mammalian cells are Ramos Burkitt's lymphoma cells.

### Claim 36 (depends on 32)

The method of claim 32, wherein said candidate polypeptide is derived from a library.

### Claim 37 (depends on 32)

The method of claim 32, wherein said viral display vector is a lentiviral vector.

### Claim 38 (depends on 32)

The method of claim 32, wherein said candidate polypeptide is an antibody or fragment thereof

### Claim 39 (depends on 37)

The method of claim 37, wherein said lentiviral vector is obtained from a lentivirus selected from the group consisting of human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), visna virus, caprine arthritis-encephalitis virus (CAEV), bovine immune deficiency virus (BIV), bovine leukemia virus (BLV), and feline immunodeficiency virus (FIV).

### Claim 40 (depends on 37)

The method of claim 37, wherein said nucleic acid vector further comprises a selectable marker.

### Claim 41 (depends on 40)

The method of claim 40, wherein said selectable marker is selected from the group consisting of a green fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, a blue fluorescent protein, a ferredoxin IV protein, a luciferase protein and a aequorin protein.

### Claim 42

A method of producing a soluble candidate polypeptide, comprising the step of:
a) contacting a packaging cell comprising with a viral display vector under conditions such that said packaging cell generates one or more viral particles, wherein said viral vector comprises:
i) a first a nucleic acid sequence encoding a fusion protein comprising:
a) a leader peptide;
b) a candidate polypeptide;
c) at least a portion of an immunoglobulin molecule; and
d) a transmembrane moiety flanked by a loxP sites
ii) a second nucleic acid sequence encoding a cre recombinase polypeptide, operably linked to an inducible promoter,
b) contacting said viral particles with a mammalian cell, under conditions sufficient to express said fusion protein and said cre recombinase in said mammalian cell, whereby a soluble candidate polypeptide is produced by said mammalian cell.

### Claim 43 (depends on 42)

The method of claim 42, wherein said candidate polypeptide is an antibody.

### Claim 44 (depends on 43)

The method of claim 43, wherein said antibody is a single chain antibody, a domain antibody, a diabody, or Fab fragment.

### Claim 45 (depends on 42)

The method of claim 42, wherein said candidate polypeptide is derived from a library.

### Claim 46 (depends on 42)

The method of claim 42, wherein said viral display vector is a lentiviral vector.

### Claim 47 (depends on 46)

The method of claim 46, wherein said lentiviral vector is obtained from a lentivirus selected from the group consisting of human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), visna virus, caprine arthritis-encephalitis virus (CAEV), bovine immune deficiency virus (BIV), bovine leukemia virus (BLV), and feline immunodeficiency virus (FIV).

### Claim 48

A viral display vector comprising a first nucleic acid sequence encoding a fusion protein comprising:
i) a leader peptide;
ii) a candidate polypeptide;
iii) at least a portion of an immunoglobulin molecule; and
iv) a transmembrane moiety; and

### Claim 49 (depends on 48)

The method of claim 48, wherein said immunoglobulin molecule comprises the hinge region, the CH2 region or the CH3 region of an IgG molecule or a combination thereof.

### Claim 50 (depends on 48)

The method of claim 48, wherein said candidate polypeptide is an antibody or fragment thereof.

### Claim 51 (depends on 50)

The method of claim 50, wherein said antibody is a single chain antibody, a domain antibody, a diabody, or Fab fragment.

### Claim 52 (depends on 48)

The method of claim 48, wherein said candidate polypeptide is derived from a library.

### Claim 53 (depends on 48)

The method of claim 48, wherein said viral display vector is a lentiviral vector.

### Claim 54 (depends on 53)

The method of claim 53, wherein said lentiviral vector is obtained from a lentivirus selected from the group consisting of human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), visna virus, caprine arthritis-encephalitis virus (CAEV), bovine immune deficiency virus (BIV), bovine leukemia virus (BLV), and feline immunodeficiency virus (FIV).

### Claim 55 (depends on 48)

The viral display vector of claim 48, wherein said first nucleic acid further comprises a selectable marker.

### Claim 56 (depends on 55)

The viral display vector of claim 55, wherein said selectable marker is a bioluminescent protein moiety.

### Claim 57 (depends on 56)

The viral display vector of claim 56, wherein said bioluminescent protein moiety is selected from the group consisting of a green fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, a blue fluorescent protein, a ferredoxin IV protein, a luciferase protein and a aequorin protein.

### Claim 58 (depends on 53)

The viral display vector of claim 53, further comprising two or more loxP sites, wherein said loxP sites flank said transmembrane moiety,

### Claim 59 (depends on 53)

The viral display vector of claim 53, further comprising a second nucleic acid sequence encoding a cre recombinase protein operably linked to an inducible promoter.

### Claim 60 (depends on 53)

The viral display vector of claim 53, wherein said first nucleic acid sequence is operably linked to an inducible promoter.

### Claim 61 (depends on 60)

The viral display vector of claim 60, wherein said inducible promoter is selected from the group consisting of a tetracycline inducible promoter, an alcohol inducible promoter, a steroid inducible promoter, a metal inducible promoter, a light inducible promoter, and a temperature inducible promoter.

### Claim 62 (depends on 53)

A vector system, comprising:
a) the viral display vector of claim 53;
b) an envelope vector comprising an env gene operably linked to a promoter and a polyadenylation sequence wherein said env gene encodes a functional envelope protein and;
(c) a helper vector comprising one or more viral structural genes.

### Claim 63 (depends on 62)

The vector system of claim 62, wherein said env gene comprises a vesicular stomatitis virus glycoprotein gene.

### Claim 64 (depends on 62)

The vector system of claim 62, wherein said one or more viral structural genes are selected from the group consisting of gag, pol, tat, and rev.

### Claim 65

A nucleic acid viral targeting vector comprising:
a) a first nucleic acid sequence encoding a fusion protein, wherein said fusion protein comprises:
i) a leader peptide;
ii) a candidate polypeptide;
iii) at least a portion of an immunoglobulin molecule; and
iv) a transmembrane moiety flanked by a loxP;
b) a second nucleic acid sequence comprising a toxin
c) a third nucleic acid sequence encoding cre recombinase operably linked to an inducible promoter; and
d) a fourth nucleic acid sequence encoding an entry moiety.

### Claim 66 (depends on 65)

The viral targeting vector of claim 65, wherein said entry moiety is selected from the group consisting of a viral envelope protein, a eukaryotic protein having fusogenic activity, a binding-defective hemagglutinin protein, and a binding-defective influenza hemagglutinin protein.

### Claim 67

A nucleic acid viral targeting vector comprising:
a) a first nucleic acid sequence encoding a fusion protein, wherein said fusion protein comprises:
i) a leader peptide;
ii) a candidate polypeptide;
iii) at least a portion of an immunoglobulin molecule;
iv) a toxin; and
v) a transmembrane moiety flanked by a loxP;
b) a second nucleic acid sequence encoding cre recombinase operably linked to an inducible promoter; and
c) a third nucleic acid sequence encoding an entry moiety.

### Claim 68 (depends on 67)

The viral targeting vector of claim 67, wherein said entry moiety is selected from the group consisting of a viral envelope protein, a eukaryotic protein having fusogenic activity, a binding-defective hemagglutinin protein, and a binding-defective influenza hemagglutinin protein.

### Claim 69

A method for the targeted delivery of a nucleic acid sequence in a subject, wherein said nucleic acid sequence encodes a fusion protein, wherein said fusion protein comprises:
i) a leader peptide;
ii) a candidate polypeptide;
iii) at least a portion of an immunoglobulin molecule;
iv) a transmembrane moiety; and
v) an entry moiety,
wherein the nucleic acid is expressed on the surface of a viral particle, and wherein the candidate polypeptide specifically binds to a target cell surface antigen, the method comprising introducing said viral particle into the subject, such that said viral particle contacts a cell expressing said target cell surface antigen under conditions such that said candidate polypeptide selectively binds to said cell and said nucleic acid transduces said cell.

### Claim 70 (depends on 69)

The viral targeting vector of claim 69, wherein said entry moiety is selected from the group consisting of a viral envelope protein, a eukaryotic protein having fusogenic activity, a binding-defective hemagglutinin protein, and a binding-defective influenza hemagglutinin protein.

### Claim 71 (depends on 22)

The method of claim 22, wherein said one or more mammalian cells express a calcium-sensitive bioluminescent protein.

### Claim 72 (depends on 71)

The method of claim 71, wherein said calcium-sensitive bioluminescent protein is aequorin.
